bupivacaine + morphine + dexmedetomidine

This entry refers to the pharmacological regimen evaluated in a clinical trial conducted by **Kafrelsheikh University** for the management of postoperative pain. The study investigates the efficacy of ultrasound-guided **adductor canal block (ACB)** using **bupivacaine**, a long-acting amide local anesthetic, in combination with either **morphine** or **dexmedetomidine** as adjuvants. Bupivacaine provides regional anesthesia by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction. Morphine, a potent opioid agonist, is added to enhance the analgesic effect through its action on mu-opioid receptors. Dexmedetomidine, a selective alpha-2 adrenergic agonist, is utilized to prolong the duration of the sensory block and reduce the requirement for rescue analgesia. This combination therapy is specifically targeted at patients undergoing knee surgeries to provide effective pain control while minimizing motor blockade and systemic opioid consumption.

Other names

ACB with Bupivacaine and AdjuvantsMorphine and Dexmedetomidine as Adjuvants to Bupivacaine in ACB